GlassScriptPhysician profile
Felix Albert Olash
NPI 1053428714
$9,974.24
in general payments reported to CMS, 2019-2025
38 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $997 · 2020: $1,256 · 2021: $2,063 · 2022: $1,869 · 2023: $1,651 · 2024: $1,057 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,789.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,743.72 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $925.33 | 2019-2025 | |
| Novo Nordisk INC | $771.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $666.26 | 2019-2025 | Leqvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $549.74 | 2019-2024 | Cycloset, Trulance, Uceris |
| Esperion Therapeutics, INC. | $461.55 | 2020-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $461.27 | 2019-2024 | Farxiga, Fasenra |
| Pfizer INC. | $461.16 | 2019-2025 | |
| Glaxosmithkline, LLC. | $431.61 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $407.92 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $360.86 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Sumitomo Pharma America, INC. | $346.29 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.40 | 2019-2025 | Jardiance, Jascayd |
| Amarin Pharma, INC. | $279.59 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $236.24 | 2022-2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avvisto Therapeutics, LLC | $228.75 | 2024-2025 | Cycloset |
| Radius Health, INC. | $155.88 | 2024-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $145.88 | 2020-2023 | Verquvo, Lagevrio, Belsomra |
| Astellas Pharma US INC | $132.39 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $126.63 | 2019-2023 | Livalo, Seglentis |
| Ardelyx, INC. | $102.41 | 2023 | Ibsrela |
| Exact Sciences Corporation | $79.37 | 2023-2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $73.89 | 2022 | |
| Eisai INC. | $66.66 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.01 | 2019 | |
| Ironwood Pharmaceuticals, INC | $52.82 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $49.17 | 2019-2020 | |
| Allergan, INC. | $41.16 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $40.78 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $37.03 | 2022-2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $35.77 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.04 | 2022 | |
| Boston Scientific Corporation | $25.01 | 2024 | Watchman Flx |
| Kyowa Kirin, INC. | $19.82 | 2020 | |
| Irhythm Technologies, INC. | $18.58 | 2024 | Zio Xt Patch, Zio Monitor |
| Philips North America LLC | $15.99 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Verona Pharma, INC. | $15.20 | 2025 | Ohtuvayre |
| Alfasigma USA, INC. | $12.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felix Olash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.